They have assessed that LCNEC patients carrying a wild-type RB1 gene or expressing the RB1 protein benefit more from platinum-based chemotherapy plus gemcitabine or taxane treatment than from standard SCLC chemotherapy (platinum plus etoposide) (15). The gene discussed is RB1; the disease is small cell lung carcinoma.